Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Paddison, Patrick J  [Clear All Filters]
Journal Article
Betschinger J, Nichols J, Dietmann S, Corrin PD, Paddison PJ, Smith A. Exit from Pluripotency Is Gated by Intracellular Redistribution of the bHLH Transcription Factor Tfe3. Cell. 2013;153(2):335-47.
Kuppers DA, Linton J, Espinosa SOrtiz, McKenna KM, Rongvaux A, Paddison PJ. Gene knock-outs in human CD34+ hematopoietic stem and progenitor cells and in the human immune system of mice. PLoS One. 2023;18(6):e0287052.
Danovi D, Folarin A, Gogolok S, Ender C, Elbatsh AMO, Engström PG, Stricker SH, Gagrica S, Georgian A, Yu D, et al. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. PLoS One. 2013;8(10):e77053.
Nayak RC, Trump LR, Aronow BJ, Myers K, Mehta P, Kalfa T, Wellendorf AM, C Valencia A, Paddison PJ, Horwitz MS, et al. Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. J Clin Invest. 2015.
Hoellerbauer P, Kufeld M, Arora S, Wu H-J, Feldman HM, Paddison PJ. A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures. Cancer Rep (Hoboken). 2020:ecnr21269.
Mitchell K, Sprowls SA, Arora S, Shakya S, Silver DJ, Goins CM, Wallace L, Roversi G, Schafer R, Kay K, et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. Genes Dev. 2023.